Sanofi and Teva to develop novel IBD treatment
Under a new agreement with Sanofi, Teva could receive up…
Under a new agreement with Sanofi, Teva could receive up to $1.5 billion for its novel anti-TL1A therapy, a potential best-in-class option for inflammatory bowel disease (IBD).